Pfizer Aktie News

This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages, including a 5% boost from Merck. My expectations are high for December's increases, with at least five companies announcing 10%+ b...

Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result ...

Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.

Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.

Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly.

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.

The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.